| Literature DB >> 35857205 |
Lena M Hassen1,2, Rana A Albarrak1, Reem A Albahlal1, Dimah K Alsaqabi3, Ikhlass M Hassen4, Maha H Daghestani2, Eman M Alqurtas1, Abdulaziz T Alkhalaf1, Mohammed K Bedaiwi1, Mohammed A Omair1, Ibrahim A Almaghlouth5,6.
Abstract
PURPOSE: The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients' functional and psychosocial states during the pandemic and assess its impact on their quality of life.Entities:
Keywords: COVID-19; Mental health; Patient-reported outcome; Quality of life; Rheumatic disease
Mesh:
Year: 2022 PMID: 35857205 PMCID: PMC9297668 DOI: 10.1007/s11136-022-03184-1
Source DB: PubMed Journal: Qual Life Res ISSN: 0962-9343 Impact factor: 3.440
Descriptive analysis of rheumatic patients’ characteristics
| Variable | Total ( |
|---|---|
| Demographic | |
| Age (years), mean (S.D.) | 36.31 (9.75) |
| Gender (male), | 179 (14) |
| Nationality (Saudi), | 1097 (85.8) |
| Marital status, | |
| Never married | 473 (37.7) |
| Currently married | 681 (53.3) |
| Previously married | 124 (9.7) |
| Educational level, | |
| Elementary education | 49 (3.8) |
| Intermediate education | 392 (30.7) |
| Higher education | 837 (65.5) |
| Employment (yes), | 446 (34.9) |
| Health condition | |
| Smoking (yes), | 69 (5.4) |
| Psychological disorder (yes), | 138 (10.8) |
| Comorbidity (yes), | 506 (39.6) |
| Rheumatic disease diagnosis (type), | |
| Rheumatoid arthritis | 551 (43.1) |
| Systemic lupus erythematosus | 399 (31.2) |
| Behçet syndrome | 40 (3.1) |
| Sjögren syndrome | 27 (2.1) |
| Rheumatoid spondylarthritis | 18 (1.4) |
| Other inflammatory disease | 131 (10.3) |
| Overlap syndrome | 112 (8.8) |
| Disease status (active), | 417 (32.6) |
Descriptive analysis of patient-reported outcomes during COVID-19 and comparison between the three time points
| Variable | Overall ( | Time 1 ( | Time 2 ( | Time 3 ( | |
|---|---|---|---|---|---|
| COVID-19 infection | |||||
| COVID-19 infection (confirmed), | 75 (5.9) | 19 (3.2) | 10 (2.8) | 46 (14.1) | < 0.001** |
| Healthcare access | |||||
| Hospital or clinic visit (no), | 429 (33.7) | 201 (33.5) | 143 (40.7) | 85 (26) | < 0.001** |
| Obtaining medication (no), | 617 (48.3) | 313 (52.2) | 152 (43.3) | 152 (46.5) | 0.023* |
| Patient perception (worry) | |||||
| Worsening disease activity, | 263 (20.6) | 109 (18.2) | 82 (23.4) | 72 (22) | 0.122 |
| Contracting COVID infection, | 703 (55) | 331 (55.2) | 203 (57.8) | 169 (51.7) | < 0.001** |
| Deteriorating disease if COVID infected, | 864 (67.6) | 399 (66.5) | 245 (69.8) | 220 (67.3) | 0.394 |
| Losing a job, | 230 (18) | 100 (16.7) | 70 (19.9) | 60 (18.3) | 0.742 |
| Patient-reported outcome | |||||
| Physical function, mean (S.D.) | 15.84 (3.71) | 16.16 (3.64) | 15.61 (3.79) | 15.50 (3.70) | 0.014* |
| Social participation, mean (S.D.) | 13.51 (4.25) | 13.85 (4.30) | 13.27 (4.27) | 13.16 (4.09) | 0.028* |
| Anxiety, mean (S.D.) | 9.57 (4.02) | 9.42 (3.89) | 9.63 (4.02) | 9.78 (4.25) | 0.403 |
| Depression, mean (S.D.) | 8.75 (4.15) | 8.52 (4.10) | 8.74 (4.04) | 9.14 (4.39) | 0.094 |
| Fatigue, mean (S.D.) | 11.82 (4.38) | 11.54 (4.33) | 11.83 (4.23) | 12.30 (4.52) | 0.042* |
| Sleep disturbance, mean (S.D.) | 12.30 (1.76) | 12.35 (1.82) | 13.34 (1.64) | 12.17 (1.76) | 0.301 |
| Pain interference, mean (S.D.) | 10.88 (4.59) | 10.48 (4.47) | 11.15 (4.68) | 11.34 (4.67) | 0.011* |
| Pain intensity (levels), mean (S.D.) | 4.63 (2.51) | 4.37 (2.48) | 4.78 (2.53) | 4.94 (2.50) | 0.002** |
**P-value is significant at the 0.01 level (2-tailed); *P-value is significant at the 0.05 level (2-tailed)
Multivariate linear regression for functional patient-reported outcomes (N = 1278)
| Predictor | Unstandardized coefficient | |||
|---|---|---|---|---|
| Physical function (PF) | Fatigue (FTG) | Sleep quality (SLP) | Pain interference (PI) | |
| Age | − 0.05 (− 0.07, − 0.04)** | 0.01 (− 0.01, 0.02) | − 0.01 (− 0.02, 0.01) | 0.04 (0.03, 0.06)** |
| Male | − 0.34 (− 0.76, 0.09) | − 0.50 (− 0.93, − 0.08)* | 0.08 (− 0.21, 0.37) | − 0.14 (− 0.59, 0.32) |
| Saudi | 0.67 (0.27, 1.08)** | – | – | − 0.65 (− 1.10, − 0.20)* |
| Marital status (single) | − 0.64 (− 0.29, − 0.98)** | – | − 0.48 (− 0.82, − 0.15)* | – |
| Education level (elementary) | − 1.43 (− 2.17, − 0.69)** | − 1.41 (− 2.17, − 0.65)** | − 0.62 (− 1.14, − 0.10)* | − 0.97 (− 1.81, − 0.13)* |
| Employed | 0.47 (0.16, 0.79)* | – | – | – |
| Smoker | – | – | − 0.30 (− 0.74, 0.14) | – |
| Psychological disorder | – | 0.76 (0.28, 1.23)* | – | – |
| Comorbidity | − 0.80 (− 1.46, − 0.14)* | − 2.20 (− 4.78, 0.38) | – | 0.56 (0.23, 0.88)** |
| Confirmed COVID-19 infection | – | – | − 0.43 (− 0.84, − 0.02)* | – |
| Disease diagnosis | – | – | 0.89 (0.08, 1.70)* (AS) | − 0.81 (− 1.16, − 0.46)** (BD) |
| Active disease activity | − 0.37 (− 0.68, − 0.06)* | 0.23 (− 0.10, 0.57) | 0.27 (0.06, 0.48)* | 0.59 (0.23, 0.95)** |
| Disease duration (years) | – | – | – | 0.04 (0.017, 0.062)** |
| Difficulty accessing healthcare | – | – | – | – |
| Difficulty obtaining medication | – | − 0.34 (− .63, − 2.27)* | – | |
| Worsening disease activity | – | 0.79 (0.40, 1.17)** | – | 0.73 (0.31, 1.14)** |
| Contracting COVID infection | – | – | – | 0.30 (− 0.03, 0.63) |
| Deteriorating disease, if infected | − 0.24 (− 0.55, 0.067) | – | – | – |
| Losing a job | – | – | – | – |
| Physical function | – | – | – | – |
| Social participation | – | − 0.07 (− 0.15, 0.02) | – | – |
| Anxiety | – | – | – | 0.05 (0.00, 0.10)* |
| Depression | – | 0.27 (0.23, 0.31)** | − 0.02 (− 0.05, 0.01) | – |
| Fatigue | − 0.13 (− 0.18, − 0.08)** | – | − 0.03 (− 0.07, 0.00) | 0.69 (0.65, 0.73)** |
| Sleep disturbance | – | – | – | − 0.12 (− 0.21, − 0.03)* |
| Pain interference | − 0.43 (− 0.48, − 0.38)** | 0.57 (0.53, 0.61)** | − 0.04 (− 0.07, − 0.01)* | – |
| Pain intensity (levels) | – | – | – | – |
AS Ankylosing spondylarthritis; BD Behçet’s syndrome; **Correlation is significant at the 0.01 level (2− tailed); *Correlation is significant at the 0.05 level (2− tailed)
Multivariate linear regression for psychosocial patient-reported outcomes (N = 1278)
| Predictor | Unstandardized coefficient | ||
|---|---|---|---|
| Anxiety (ANX) | Depression (DEP) | Social participation (SP) | |
| Age | − 0.02 (− 0.04, 0.00) | − 0.09 (− 0.11, − 0.07)** | − 0.05 (− 0.06, − 0.03)** |
| Male | 0.50 (0.02, 0.98)* | − 0.26 (− 0.80, 0.27) | − 0.31 (− 0.77, 0.15) |
| Saudi | – | – | – |
| Marital status (single) | − 0.47 (− 0.85, − 0.09)* | 0.48 (0.05, 0.90)* | – |
| Education level (elementary) | – | – | – |
| Employed | – | – | – |
| Smoker | − 0.57 (− 1.28, 0.15) | 0.58 (−0.22, 1.38) | – |
| Psychological disorder | – | 1.62 (1.06, 2.19)** | – |
| Comorbidity | – | 0.19 (−0.18, 0.55) | – |
| Confirmed COVID-19 infection | 0.66 (− 0.01, 1.34)* | – | – |
| Disease diagnosis | – | 1.82 (0.61, 3.03)* (SS) | − 0.51 (− 1.05, 0.03) (RA) |
| Active disease activity | – | – | – |
| Disease duration (years) | – | – | – |
| Difficulty accessing healthcare | 0.49 (0.16, 0.82)* | – | − 0.46 (− 0.79, − 0.14)* |
| Difficulty obtaining medication | – | – | – |
| Worsening disease activity | – | − 0.39 (− 0.84, 0.06) | – |
| Contracting COVID infection | 1.20 (0.84, 1.56)** | 0.83 (0.47, 1.19)** | – |
| Deteriorating disease, if infected | 0.62 (0.23, 1.00)* | – | – |
| Losing a job | 0.35 (0.02, 0.69)* | 0.84 (0.39, 1.29)** | – |
| Physical function | – | – | – |
| Social participation | – | – | – |
| Anxiety | – | – | – |
| Depression | 0.50 (0.46, 0.55)** | – | − 0.05 (− 0.09, 0.00)* |
| Fatigue | 0.14 (0.09, 0.18)** | 0.37 (0.31, 0.44)** | − 0.19 (− 0.25, − 0.13)** |
| Sleep disturbance | – | − 0.08 (− 0.18, 0.03) | – |
| Pain interference | – | 0.17 (0.11, 0.23)** | − 0.50 (− 0.56, − 0.45)** |
| Pain intensity (levels) | – | – | – |
RA Rheumatoid arthritis, SS Sjögren syndrome
**Correlation is significant at the 0.01 level (2-tailed); *Correlation is significant at the 0.05 level (2-tailed)